



STATE MEDICAID DUR BOARD MEETING
 THURSDAY, May 14, 2009
 7:00 a.m. to 8:30 a.m.
 Cannon Health Building
 Room 125



MINUTES

Board Members Present:

Mark Balk, PharmD.
Derek Christensen, R.Ph.
Dominic DeRose, R.Ph.
Joseph Yau, M.D.

Peter Knudson, D.D.S.
Tony Dalpiaz, PharmD.
Colin VanOrman, M.D.

Board Members Excused:

Neal Catalano, R.Ph.
Bradley Pace, PA-C

Joseph Miner, M.D.
Bradford Hare, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.
Lisa Hulbert, R.Ph.
Jennifer Zeleny, CphT, MPH
Carol Runia

Merelynn Berrett, R.N.
Duane Parke, R.Ph.
Connie Keuffel, R.N.
Brenda Strain

Other Individuals Present:

Mariane Paul, U of U
 Bryan Larson, U of U
 Gary Oderda, U of U
 Sue Heineman, Pfizer
 Scott Clegg, Lilly

Dan Heincy, Merck
 Ann Gustafson, GSK
 Andrea Nelson, Lilly
 Glen Hodding, Roche
 Mark Crosby, IHC

Ben Campbell, U of U
 Jon Williams, GSK
 Stephen Farmer, Amgen
 Gary Bailey, Forrest

Meeting conducted by: Colin VanOrman

-
1. Minutes for April 2009 were reviewed. Mark Balk moved to accept the minutes. Dr. Lehmann seconded the motion. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.
 2. P&T Committee Update: Duane Parke addressed the Board. The P&T Committee was unable to seat a quorum last month. The agenda items for April will be addressed in May. Additionally, Medicaid will be requiring a PA starting on 5/18/09 for non-preferred drugs. A request form for the PA is in the works.
 3. Election of a New Chairman: Dr. Knudson nominated Dr. Lehmann and Mark Balk

seconded the nomination. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.

4. Candida PA Review: Lisa Hulbert addressed the Board. This is being brought before the Board due to some new FDA indications. Medicaid would like the Board to consider coverage down to 3 months of age and adding use as an empirical therapy for presumed fungal infections in febrile and neutropenic patients.

Tony Dalpiaz moved to add these new indications to the PA criteria. Mark Balk seconded the motion. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.

5. Tassigna PA Review: Lisa Hulbert addressed the Board. This is a request to update the criteria with new FDA approved indications.

Mark Balk moved to update the criteria. Dr. Lehmann seconded the motion. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.

6. Osteoporosis Class Review: Bryan Larson, Pharm D., with the University of Utah Drug Regimen Review Center addressed the DUR Board and presented a set of guidelines for the diagnosis and pharmacological management of osteoporosis.

Duane Parke asked if a bisphosphonate and teraperitide should ever be used together. They should never be used together.

Duane Parke asked if calcium and vitamin D were necessary or optional with these therapies. They are requisite to go along with these therapies. Lisa Hulbert indicated that she was researching whether or not these would be eligible for FFP, or if they would need to be covered with all state funds.

Glenn Hodding, Pharm D., with Roche addressed the Board regarding the advantages of Boniva. He provided handouts to the Board to support his remarks.

Andrea Nelson with Eli Lilly addressed the Board regarding the advantages of raloxefine and teraperitide.

Duane Parke asked if either raloxefine and teraperitide would ever be used concomitantly with a bisphosphonate. The concomitant use of a bisphosphonate and teraperitide is contraindicated because they compete with each other. The concomitant use of bisphosphonate and raloxefine, although not contraindicated, has no added benefit.

Dr. Lehmann stated that many publications now state the benefits of Vitamin D, and it is difficult for patients to find that Medicaid will not cover them when doctors prescribe them. Tim Morley stated that Medicaid does cover the Vitamin D analogs, but has not traditionally covered Vitamin D. Medicaid would consider making the OTC Vitamin D available with a prescription if the Board were to make that recommendation.

Mark Balk stated that with 15 people in a year using Forteo, there really is not a problem.

Lisa Hulbert suggested that Medicaid could investigate the possibility of concomitant use of Forteo and bisphosphonates and return to the DUR Board if a problem is found.

Derek Christensen recommended an educational piece in the Amber Sheet regarding Vitamin D. Once the DUR Board comes to a conclusion on how to handle this, an educational piece should be published.

Mark Balk recommended that the state investigate whether or not it is possible to pay for Vitamin D and return to the DUR Board with a policy proposal.

Dr. Knudson moved to officially make these recommendations to Medicaid. Mark Balk seconded the motion. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.

7. Pristiq Quantity Limits: Ben Campbell, Pharm D., of the University of Utah Drug Regimen Review Center addressed the Board regarding the safety and efficacy of Pristiq, and the place of Pristiq in the American Psychiatric Association guidelines for the treatment of depression.

Mark Balk asked if hypertension, which is a common side-effect with venlafaxine, is smaller in desvenlafaxine. Hypertension is a dose-dependant side-effect in venlafaxine, with an incidence as high as 13% seen in doses around 300mg. The incidence with desvenlafaxine is smaller, but only lower doses of that drug were tested.

Lisa Hulbert stated that Medicaid does not have any PA for other anti-depressants, but wanted to consider tracking the use of 100mg tablets due to the added safety concerns and consider monthly quantity limits or ICD 9 code tracking.

Dr. Yau stated that the algorithms and treatment for depression are not that clear. It is not uncommon for patients to go through trials of different medications, with varying degrees of success. This particular medication is a metabolite of an existing medication that may be beneficial for patients that have not responded to Effexor due to some issues with their metabolism of the parent drug.

The Board asked if other mental health drugs have quantity limits. Currently, Cymbalta does have monthly quantity limits.

Dr. Lehmann moved to limit Pristiq to 30 tablets in 30 days. Derek Christensen seconded the motion. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.

8. Tim Morley addressed the Board. He stated that the APA guidelines that were just discussed in relation to the treatment of depression did address cost as a clinical issue that should be considered in selecting a treatment. Currently, the DUR Board cannot discuss cost. He asked Dr. Knudson if there was anything that the DUR Board could do, as a

body, to recommend to the Legislature that cost could be considered in their discussions.

Dr. Knudson said that the Board could make such a recommendation, and that it would be very helpful for the Legislature to know the DUR Board's thinking on this issue.

Mark Balk stated that a pharmacoeconomic analysis should include the total cost of care and patient outcomes rather than a simplistic analysis of which tablet is cheaper than the other.

Dr. Knudson moved that the DUR Board make a recommendation to the Legislature on this issue following the dialogue of the Board. Derek Christensen seconded the motion. The motion passed unanimously with votes by Tony Dalpiaz, Dominic DeRose, Dr. Lehmann, Derek Christensen, Dr. Yau, Mark Balk, Dr. Knudson, and Dr. VanOrman.

Next meeting set for June 11, 2009

Meeting adjourned.

The DUR Board Prior Approval Subcommittee convened and considered 5 petitions.

Minutes prepared by Jennifer Zeleny